Current through September 17, 2024
Prior to prescribing, dispensing, or administering cross-sex
hormones for the treatment of gender nonconformity or gender dysphoria to a
patient who has not reached the age of majority, the prescribing practitioners
must meet the following:
(A) Obtain
three hours of Category 1 Continuing Competency Education for prescribing drugs
for the purpose of treating gender nonconformity or gender dysphoria within the
most recent biennial renewal period;
(B) Determine or document:
(i) Puberty blocking treatment, if occurring,
has been successful at reducing patient distress and discomfort;
(ii) That gender nonconformity or gender
dysphoria is driving the patient's distress and not other mental or physical
health conditions, that there is no reasonable expectation of natural
resolution of gender nonconformity, and that there has been a long-lasting and
intense pattern of gender nonconformity or gender dysphoria which began or
worsened at the start of puberty;
(iii) There is an expectation of increased
distress if puberty blocking treatment is terminated or cross-sex hormone
treatment is not initiated;
(iv)
Cross-sex hormones would be effective and are not likely to negatively impact,
or exacerbate other mental or physical health conditions;
(v) The patient has received at least 40
contact hours of therapeutic treatment as required by this chapter;
(vi) The patient has at least six consecutive
months of living primarily as the preferred gender and has continued living
primarily as the preferred gender;
(vii) For individuals not suffering from
gender dysphoria or for whom a clinical diagnosis of gender dysphoria is not
available, documentation that without cross-sex hormone treatment the patient
will experience harm; and
(viii)
The appropriate supports are in place for the patient including appropriate
social, and familial support prior to initiating cross-sex hormone
treatment;
(C) Discuss
the following with the patient and parent or legal guardian or the patient, if
the patient is an emancipated minor:
(i) The
recommended dosage and route of treatment for the cross-sex hormones;
and
(ii) The minimum waiting period
of seven calendar days as required by this chapter;
(D) Obtain signed informed consent and
patient assent as required by this chapter; and
(E) Document all the foregoing in the
patient's medical record.
